Close Menu

technology commercialization

Frameshift plans to commercialize two applications: one for data quality control and a second for identifying mutations in rare and Mendelian disorders.

Its first client, Haystack Bio, will use Genecloud to analyze and store single-cell genomics data for a proprietary platform it is developing for the immunotherapy market.

The partners have integrated WashU's VarScan with Appistry's GenomePilot, which provides preconfigured workflows for clinical NGS.

DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.

The company is currently recruiting early adopters to put Mastermind, its proprietary database of curated genomic variants, through its paces prior to full launch next year. 

The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.

The firm plans to launch several products based on its proprietary machine learning method for identifying variants that alter cellular biochemistry and cause disease.

The firm plans to begin offering a cloud-based version of its software as well as a possible appliance by the end of the summer.

The offering will use a method of constructing mate-pair libraries and accompanying software designed to work with the unique style and format of its library data.

The Singapore Agency for Science and Technology Research has launched a new Diagnostics Development Hub to help develop and commercialize diagnostic tests.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.